Costs of generic drugs and outpatient services targeted
The proposed measures include pilot projects for the financing of outpatient clinics.
Keystone
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland.
This content was published on
2 minutes
swissinfo.ch/urs
Interior Minister Alain Berset, whose portfolio includes health issues, on Friday presented plans to allow health insurers, health service providers and cantonal authorities to launch pilot projects to test innovative financing methods for hospital care or outpatient services.
The package will go to a consultation among political parties, organisations and institutions involved before parliament is due to discuss the final proposals. It is expected to lead to a savings of several hundred million francs per year, according to Berset.
He added that it won’t be easy to find support for all the proposed measures, given the ongoing dispute between insurers, doctors, the pharmaceutical industry and cantonal authorities, notably about a billing system for doctors.
Mixed reaction
In an initial reaction, the industry associations of Swiss pharmacistsExternal link and producers of generics have rejected the government proposal. They warned that patients would no longer be free to choose their favourite therapy.
For their part, the association of health insurers welcomed the plans , saying they were a step in the right direction.
SantésuisseExternal link notably called for cheaper drugs prices and more say in the construction of hospitals and nursing homes as well as increased cost transparency.
Financial caps
A second package of proposals is expected to be presented next year, including financial caps for medical costs, as recommended by a group of experts in 2016.
Overall health costs in Switzerland are about CHF80 billion ($82.6 billion) annually, including CHF30 billion covered by the mandatory health insurance plans.
The Swiss healthcare system is known for its excellent level of care, but is also among the most expensive in the world.
Popular Stories
More
Foreign affairs
What Trump’s return or a new Harris administration would mean for Switzerland
Should raw milk sales be banned or should consumers decide?
Swiss food regulations do not allow raw milk to be sold for direct consumption. However, a loophole allows 400 raw milk vending machines to do just that.
COP29: Swiss NGOs call for strong financial support
This content was published on
Ahead of COP29, Swiss NGOs call for wealthy nations to pay $1,000 billion a year to help other countries solve climate problems.
Real Swiss wages likely to rise in 2025, says UBS bank
This content was published on
Higher wages and falling inflation are likely to boost Swiss purchasing power, which will be dragged back by rising health premiums.
This content was published on
Switzerland has a new tectonic map at a scale of 1:500,000, containing updates to geometry, distribution and nomenclature of the tectonic units.
This content was published on
Swiss artist Daniel Spoerri, known for his artworks using leftover food with dirty cutlery and crockery, has passed away in Vienna at the age of 94.
Climate change tipped to alter Swiss avalanche patterns by 2100
This content was published on
Climate change is expected to result in fewer avalanches overall in Switzerland but to increase the danger of wet snow avalanches by 2100.
National conference divided on how to halt rising healthcare costs
This content was published on
The fifth Swiss national health conference on Monday centred on one major bugbear: costs. Attendees were divided on how to halt the rise.
This content was published on
The Swiss spend more from their own pockets for health care than any other nation, according to a survey for the price comparison website Comparis.
This content was published on
Interior Minister Alain Berset says he is willing to consider the introduction of a global budget for Switzerland’s healthcare system as part of efforts to reduce rising health costs.
This content was published on
In an era where health care is a subject of debate in many countries, is the Swiss system serving those on moderate to low incomes?
Novartis’s new $475,000 cancer drug among most expensive ever
This content was published on
Bruno Strigini, chief executive of oncology at Novartis, said: “We carefully considered the appropriate price and looked at many factors, including the medical and clinical value.” He was speaking on Wednesday shortly after the treatment was approved by the US Food and Drug Administration (FDA), which gave Novartis a green light to use the medicine…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.